27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Dementia risk was significantly higher in patients with epilepsy compared with that of controls (IRR: 3.65; 95% CI: 3.14-4.24), especially within the first 2 years post-diagnosis (aHR: 5.42; 95% CI: 4.30-6.83), peaking between 8 and 10 years (aHR: 8.25; 95% CI: 3.15-21.5). 5 key findings →
Design: cohort study Participants: 2,740 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Parkinson's disease (PD) is a neurodegenerative condition that may affect both motor and cognitive function. 1 key finding →
Design: longitudinal study Participants: 115 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Significant hazard ratios (HRs) for dementia incidence were found using the MMSE cutoff between 23 and 24 point (HR 1.93, 95% CI 1.13-3.27) and the J-Cog cutoff between 43 and 44 points (HR 2.42, 95% CI 1.50-3.93). 4 key findings →
Design: case-control study Participants: 100 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Delirium screening was performed exclusively in patients aged ≥75 years, accounting for 7.3% of all surgical patients. 5 key findings →
Participants: 23,100 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The final model, which included age, systolic blood pressure >140, atrial fibrillation, and tobacco use, achieved an AUC of 0.83 (95% CI 0.75-0.90) in the development cohort (N=143, 62.4±12.6 years, 44% female, 36% non-white race) and 0.85 (95% CI 0.77-0.92) in the validation cohort (N=127, 65.2±16.8 years, 51% female, 34% non-white race), with similar results using WMH measurements derived from cMRI (N=120, p=0.98, AUC=0.86, 95% CI 0.77-0.93). 5 key findings →
Participants: 143 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Design diagnostic accuracy study. 1 key finding →
Participants: 419 Evidence: low
Full summary, score breakdown and related studies → Original source
The BHA had excellent combined sensitivity and specificity to detect dementia and MCI, including MCI due to diverse etiologies. 2 key findings →
Design: cross-sectional Participants: 347 Evidence: low
Full summary, score breakdown and related studies → Original source
Aβ misfolding and GFAP showed a strong ability to predict clinical AD risk and may be important early AD risk markers. 1 key finding →
Participants: 68 Evidence: moderate
Full summary, score breakdown and related studies → Original source
When validated with subjects diagnosed using an official test, the model achieves COVID-19 sensitivity of 98.5% with a specificity of 94.2% (AUC: 0.97). 5 key findings →
Participants: 19 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is one of the most common neurodegenerative diseases. 1 key finding →
Participants: 647 Evidence: low
Full summary, score breakdown and related studies → Original source
Service utilization by demented patients increases already within the year before the first diagnosis and stays on a relatively high level within the year after. 1 key finding →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Plasma p-tau181 differentiates AD pathology cases from NC with high accuracy. 4 key findings →
Participants: 91 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Among 356 patients (79%) with AD as the primary suspected etiology, assessment of BBM classified 149 patients (42%) as high, 101 patients (28%) as intermediate, and 106 patients (30%) as low probability of AD. 5 key findings →
Design: cohort Participants: 450 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Plasma phosphorylated tau (p-tau)181, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and amyloid beta ratio (Aβ42/40) may have diagnostic and prognostic value in Alzheimer's disease (AD). 2 key findings →
Design: cross-sectional Participants: 1,298 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The results of this study suggest that naftidrofuryl is effective and well tolerated in treating the symptoms of vascular and mixed dementia. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The correct diagnosis of Parkinson's disease is important for prognostic and therapeutic reasons and is essential for clinical research. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Key experiments using fibril-free AβO solutions demonstrated that while Aβ is essential for memory loss, the fibrillar Aβ in amyloid deposits is not the agent. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We conducted full diagnostic evaluations, including a comprehensive cognitive assessment battery, of a group of 32 elderly subjects with a clinically identified mild cognitive impairment and a group of 32 age-matched and education-matched normal subjects. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A diagnosis of dementia is devastating at any age but diagnosis in younger patients presents a particular challenge. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Despite its potential benefits, few published studies have explored the advantages or risks of a timely diagnosis of AD. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Severe, and often fatal, neuroleptic sensitivity may occur in elderly patients with confusion, dementia, or behavioural disturbance. 3 key findings →
Participants: 21 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The concept of mild cognitive impairment (MCI) draws attention to cognitive changes not severe enough to warrant the diagnosis of dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Synucleinopathies are clinically and pathologically heterogeneous disorders characterized by pathologic aggregates of α-synuclein in neurons and glia, in the form of Lewy bodies, Lewy neurites, neuronal cytoplasmic inclusions, and glial cytoplasmic inclusions. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A brief diagnostic battery of neuropsychological tests was developed for a large-scale epidemiological study of dementia. 3 key findings →
Participants: 12 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Florbetapir F18 has been approved by the Food and Drug Administration for in vivo assessment of amyloid pathology in patients undergoing evaluation for Alzheimer disease (AD). 3 key findings →
Participants: 229 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
10 of the 1,775 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →